NEW YORK (GenomeWeb News) – Insight Genetics today announced it was awarded a $1.5 million Phase II Small Business Innovation Research contract from the National Cancer Institute to continue development of a diagnostic test aimed at non-small cell lung cancer.

The Fast Track contract will go toward the further development of a panel of assays for identifying and characterizing ongogenic ROS1, RET, and DEPDC1 in a population of NSCLC patients who are triple negative for mutations in EGFR, KRAS, or ALK, the Nashville, Tenn.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.